Terminated PHASE3 INTERVENTIONAL 2-arm NCT01940887

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.

Sponsor: Ophthotech Corporation

Conditions Age-Related Macular Degeneration

Interventions E10030 E10030 sham injection bevacizumab or aflibercept

Updated 12 times since 2017 Last updated: Oct 19, 2024 Started: May 31, 2014 Primary completion: Jun 30, 2017 Completion: Sep 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Ophthotech Corporation

More terminations from Ophthotech Corporation

Other Age-Related Macular Degeneration trials with similar outcome

Browse all Age-Related Macular Degeneration trials

A PHASE3 clinical study on Age-Related Macular Degeneration, this trial is terminated or withdrawn. The trial is conducted by Ophthotech Corporation and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Nov 2024 — Sep 2025 [monthly]

Terminated PHASE3
Sep 2024 — Nov 2024 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Mar 2024 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 7 earlier versions

Jan 2021 — Mar 2024 [monthly]

Terminated PHASE3
Oct 2020 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2020 — Oct 2020 [monthly]

Terminated PHASE3
Jun 2018 — Feb 2020 [monthly]

Terminated PHASE3
Sep 2017 — Jun 2018 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ophthotech Corporation

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aachen, Germany , Abilene, United States , Albacete, Spain , Albuquerque, United States , Albury, Australia , Altamonte Springs, United States , Amarillo, United States , Ancona, Italy , Asheville, United States and 164 more locations